Russia
· Delayed Price · Currency is RUB Artgen Biotech PJSC Company Description
Artgen Biotech PJSC, a biotech company, engages in the development of healthcare products in Russia.
It develops Betuvax-CoV-2, a vaccine for SARS-COV-2; Tetraflubet, a Flu vaccination; Combi 5V, a Flu + COVID-19 booster vaccine; Betusphere for Immunomodulator; RBT-402, a HPV vaccine; and RBT-501, a vaccine for natural allergy.
The company also offers Histograft, a Gene-activated material used as an osteoplastic material, as well as biobanking, genetic research, and regenerative medicine services.
In addition, it develops various medical products, such as Xeno-Bone for bone grafting in open operations; Inject-Bone for minimally invasive bone grafting; Inject-Soft use for damage to the skin and mucous membranes; 3D-Bone use for replacement od volumetric bone defects; Cover Bone for guided bone regeneration; and Supl-Bone for bone grafting.
The company was formerly known as Public Joint-Stock Company "Human Stem Cells Institute". The company was founded in 2003 and is based in Moscow, Russia.
| Country | Russia |
| Founded | 2003 |
| Industry | Biological Products, Except Diagnostic Substances |
| CEO | Prikhodko Viktorovich |
Contact Details
Address: st. Gubkina d.3, building 2 Moscow, 119333 Russia | |
| Phone | 7 495 646 8076 |
| Website | artgen.ru |
Stock Details
| Ticker Symbol | ISKJ |
| Exchange | Moscow Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | RUB |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Prikhodko Viktorovich | Chief Executive Officer |
| Bulanova Igorevna | Chief Financial Officer |